Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Mobidiag, Genewave and Amplidiag Announce Definitive Agreement

Published: Monday, April 15, 2013
Last Updated: Monday, April 15, 2013
Bookmark and Share
The new Mobidiag to offer integrated, high-multiplex diagnostic tests for infectious diseases.

Mobidiag Oy/Ltd, Genewave SAS, and Amplidiag Oy have announced a definitive agreement to combine the three companies to create a technology leader in molecular diagnostics for infectious diseases.

The new Mobidiag combines Mobidiag’s and Amplidiag’s high-multiplex proprietary diagnostic test portfolios with Genewave’s automated and integrated test platform.

The merger was accompanied by a financing round by existing investors Helsinki University Fund, iXLife, Tutor Invest (Medtech Rahasto Ky), and others, as well as public funding support from the Finnish funding agencies, Tekes and Finnvera, and the EU.

Joining as Mobidiag’s new CEO is Tuomas Tenkanen, the former R&D Director of the diagnostics PCR products provider, Finnzymes Oy, which was acquired by Thermo Fisher Scientific.

The transaction was effected as a share exchange, upon which Genewave and Amplidiag became subsidiaries of Mobidiag Oy/Ltd.

The new company is headquartered in Helsinki, with a center of excellence in Paris, and now has the diagnostic test pipeline, integrated test platform, leadership, infrastructure, and financial resources to develop and bring to commercialization its automated instrument and panel of diagnostic tests, capable of identifying a large number of pathogens from a single patient sample.

“The fusion of these three complementary companies creates a unique opportunity to bring forward the next generation of infectious disease diagnostics to dramatically improve global health care,” said Tuomas Tenkanen, CEO, Mobidiag.

Genewave specializes in the development, manufacturing and marketing of cutting-edge microarray instrumentation for diagnostic, clinical and life science research.

Genewave’s innovative GeneSpress® system is an automated and integrated platform for highly multiplexed molecular diagnostic tests.

The compact system integrates DNA purification, PCR amplification and microarray hybridization and detection into an automated workflow on a single, closed lab-on-chip cartridge.

Among other innovative features, the platform incorporates Genewave’s patented TouchArray™ optical detection technology for highly sensitive imaging of microarrays.

Mobidiag’s clinically proven, CE-IVD marked Prove-it™ diagnostic tests enable up to 84 pathogens and antibiotic resistance markers to be detected in a single assay, representing cutting-edge multiplexing capabilities.

Current test products are intended for diagnosing bacterial and fungal sepsis, viral central nervous system infections and bacterial bone and joint infections. Mobidiag has built a reference customer base with its current test portfolio and has generated market acceptance in Europe.

The automation of Mobidiag’s tests will answer the need of clinical laboratories for automated and integrated solutions for diagnostic testing of severe infectious diseases.

Amplidiag provides a broad panel of diagnostic tests for infectious diseases. Amplidiag has substantial intellectual property covering testing and nucleic acid extraction methods for contagious gastrointestinal and other serious diseases.

The global molecular diagnostics market exceeds 5 billion EUR, and is growing more than 15% annually.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Mobidiag and Unilabs Enter into Agreement
The agreement solidifies Unilabs’ position as an industry-leading diagnostics service provider and is a major milestone for Mobidiag in European market entry.
Tuesday, September 01, 2015
Mobidiag Announces CE Marking of Amplidiag™ H. pylori+ClariR
Test is first-to-market, non-invasive IVD assay for reliable detection of both Helicobacter pylori and clarithromycin resistance from stool sample.
Wednesday, June 03, 2015
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
Nanoparticles Target, Transform Fat Tissue
Nanoparticles designed to target white fat and convert it to calorie-burning brown fat slowed weight gain in obese mice without affecting food intake. This proof-of-concept work could lead to new therapies to treat obesity.
New Cancer Fighters Emerge From Lab
Rice University lab simplifies total synthesis of anti-cancer agent.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!